Patent application number | Description | Published |
20100022506 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 01-28-2010 |
20110021492 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 01-27-2011 |
20110028446 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 02-03-2011 |
20120041190 | MACROCYCLES AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 02-16-2012 |
20120270853 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 10-25-2012 |
20140243338 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS - The present invention provides compounds of Formula (I): | 08-28-2014 |
20150112058 | MACROCYCLES AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 04-23-2015 |
20160002172 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS - The present invention provides compounds of Formula (I): (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same. | 01-07-2016 |